Drug intelligence / Profile preview

GenAhead Bio SFTS antiviral oligonucleotide

Development stage: Preclinical
Lead developer: GenAhead Bio
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

GenAhead Bio is developing an antiviral oligonucleotide therapeutic for the treatment of Severe Fever with Thrombocytopenia Syndrome (SFTS), a tick-borne viral disease. Developed in collaboration with the Japan Institute for Health Security and the National Institute of Infectious Diseases, the therapeutic consists of silencing nucleic acid sequences rationally designed to target the SFTS virus genome. The drug is intended to inhibit viral replication through RNA silencing mechanisms. The program is currently in the preclinical research stage, leveraging GenAhead Bio's expertise in nucleic acid delivery and genome editing technologies.

Other names: SFTS virus-oligonucleotide (antiviral)

Targets

SFTSV genomic RNA (Severe fever with thrombocytopenia syndrome virus genomic RNA)

Beyond the preview

Go deeper on GenAhead Bio SFTS antiviral oligonucleotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenAhead Bio SFTS antiviral oligonucleotide.

Explore the full profile